_A01: Financing Network Durability

First Page		Document Content
Date: 2014-05-02 12:07:18 Research Muscular dystrophy Pharmaceutical industry Motor neurone disease Rare diseases TREAT-NMD Duchenne muscular dystrophy Clinical trial Amyotrophic lateral sclerosis Health Medicine Clinical research		_A01: Financing Network Durability Add to Reading List Source URL: www.rare-diseases.eu Download Document from Source Website File Size: 571,73 KB Share Document on Facebook

	Microsoft Word - ASX 17_ 2 October_ ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Update summary_Final DocID: 1ulfx - View Document
	19 DecemberATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Update Antisense Therapeutics Limited (“ANP” or “the Company”) provides the following update on the progress of its Multiple Sclero DocID: 1tPwS - View Document
	FINAL Catabasis Pharmaceuticals Announces the Initiation of an Open-Label Extension for the MoveDMD® Trial Studying Edasalonexent (CATin Duchenne Muscular Dystrophy CAMBRIDGE, MA, July 7, 2016 – Catabasis Phar DocID: 1t5Sx - View Document
	Screening S. aureus CRISPR-Cas9 Paired Guide RNAs for Efficient Targeted Deletion in Duchenne Muscular Dystrophy Josh Tycko1, Nick Huston1, Jacqueline Robinson-Hamm2, Chris Wilson1, Charles A. Gersbach2, Patrick D. Hsu1, DocID: 1sCDI - View Document
	Research Review No. 96. Therapeutic effect of simvastatin to Duchenne Muscular Dystrophy. The Studies: The authors of this study (1) from U.S.A. note in their introduction that Duchenne muscular dystrophy (DMD) is a le DocID: 1rWwv - View Document